SE
SENS.US Senseonics Holdings, Inc. Common Stock
- Market cap
- USD 592M
- P/E
- -
- P/B
- 7.47x
- ROE
- -174.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SENS.US undervalued?
Graham numberThe Graham number of Senseonics Holdings, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Senseonics Holdings, Inc. Common Stock fundamental analysis
No fundamental analysis for Senseonics Holdings, Inc. Common Stock yet.
Senseonics Holdings, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Senseonics Holdings, Inc. Common Stock
Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. Its products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a…
Full company profileSenseonics Holdings, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Senseonics Holdings, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 332K | 6.37M | 18.9M | 21.3M | 4.95M | 13.7M | 16.4M | 22.4M | 22.5M | 35.3M | 61.0M |
| Gross Profit | -328K | -3.39M | -8.15M | -19.4M | -17.4M | -811K | 2.73M | 3.09M | 533K | 15.8M | 36.8M |
| Operating Income | -42.4M | -56.3M | -87.6M | -131M | -79.1M | -57.2M | -68.6M | -75.6M | -74.8M | -68.3M | -133M |
| EBITDA | -42.2M | -55.8M | -85.4M | -99.4M | -158M | -285M | 162M | -48.0M | -68.7M | -62.7M | -130M |
| Net Income | -43.9M | -59.1M | -94.0M | -116M | -175M | -302M | 142M | -60.4M | -78.6M | -69.1M | -136M |
| EPS | -9.84 | -10 | -12 | -12 | -15 | -14 | 4.60 | -2.13 | -2.50 | -1.66 | -2.06 |
| Balance Sheet | |||||||||||
| Total Assets | 22.3M | 45.9M | 160M | 133M | 35.9M | 199M | 178M | 138M | 100M | 126M | 163M |
| Total Liabilities | 27.1M | 38.7M | 88.7M | 141M | 180M | 384M | 180M | 102M | 117M | 65.2M | 84.9M |
| Shareholders' Equity | -4.88M | 7.27M | 71.3M | -8.65M | -144M | -186M | -2.58M | 35.8M | -16.6M | 61.0M | 77.6M |
| Cash & Short-term Investments | 20.3M | 36.5M | 137M | 95.9M | 18.0M | 130M | 144M | 109M | 74.6M | 94.0M | 126M |
| Total Debt | 19.2M | 24.5M | 51.0M | 119M | 62.7M | 64.2M | 75.4M | 47.8M | 61.1M | 41.4M | 61.1M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -38.0M | -55.7M | -90.8M | -136M | -67.4M | -56.1M | -66.3M | -70.2M | -60.5M | -59.1M | -127M |
| Capital Expenditure | 479K | 345K | 989K | 1.05M | 181K | 210K | 312K | 350K | 2.24M | 1.12M | 751K |
| Free Cash Flow | -38.5M | -56.1M | -91.8M | -137M | -67.6M | -56.3M | -66.6M | -70.5M | -62.7M | -60.2M | -128M |
| Ratios | |||||||||||
| ROE | - | -813.3% | -131.9% | - | - | - | - | -168.7% | - | -113.2% | -174.7% |
| ROA | -197.3% | -128.6% | -58.7% | -87.0% | -487.7% | -152.1% | 80.0% | -43.7% | -78.3% | -54.7% | -83.5% |
| Net Profit Margin | -13,231.9% | -927.4% | -496.9% | -542.5% | -3,539.5% | -2,211.9% | 867.2% | -269.7% | -349.8% | -196.0% | -222.3% |
| Debt to Equity | - | 3.37x | 0.72x | - | - | - | - | 1.33x | - | 0.68x | 0.79x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Senseonics Holdings, Inc. Common Stock dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 2.57M | 0.08 | 1.8% |
| 2021 | USD 5.29M | 0.25 | - |
| 2020 | USD 550K | 0.05 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:20 on Oct 20, 2025.
Who owns Senseonics Holdings, Inc. Common Stock
- Insiders 9.53%
- Institutions 41.71%
- Public & others 48.77%
- Shares outstanding 54.8M
- Free float 45.6M
Top funds holding SENS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.62M | 2.95% | +37.59% | Sep 2026 |
| iShares Russell 2000 ETF | 948K | 1.73% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 437K | 0.80% | +1.68% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 353K | 0.64% | -0.38% | Oct 2026 |
| CREF Total Global Stock Account R3 | 283K | 0.52% | +334.15% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 260K | 0.47% | +0.23% | Oct 2026 |
| Fidelity Extended Market Index | 228K | 0.42% | -6.94% | Sep 2026 |
| Vanguard Russell 2000 ETF | 219K | 0.40% | -3.42% | Sep 2026 |
| Invesco Dorsey Wright SmallCap Momt ETF | 160K | 0.29% | -0.54% | Oct 2026 |
| iShares Micro-Cap ETF | 115K | 0.21% | 0.00% | Oct 2026 |
| Stt Strt® SPDR® S&P®HlthCrEqpmntETF | 92.4K | 0.17% | 0.00% | Oct 2026 |
| Schwab Small Cap Index | 91.5K | 0.17% | -4.68% | Sep 2026 |
| Fidelity Total Market Index | 89.5K | 0.16% | -0.05% | Sep 2026 |
| iShares Core S&P Total US Stock Mkt ETF | 89.1K | 0.16% | +0.03% | Oct 2026 |
| Bridge Builder Small Cap Fund | 87.7K | 0.16% | 0.00% | Oct 2026 |
| F/m Emerald Life Sciences Innovation ETF | 76.2K | 0.14% | 0.00% | Oct 2026 |
| Fidelity Series Total Market Index | 75.4K | 0.14% | 0.00% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 68.1K | 0.12% | -7.66% | Sep 2026 |
| Stt Strt SPDR® Russell2000 US SmCapETF | 63.1K | 0.12% | -5.89% | Oct 2026 |
| EA Bridgeway Ultra-Small Company Mkt ETF | 60.4K | 0.11% | 0.00% | Oct 2026 |
Top institutions holding SENS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Sessa Capital, L.P | 4.44M | 8.10% | +151.26% | Jun 2026 |
| BlackRock Inc | 2.79M | 5.10% | +391.19% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.78M | 3.25% | +10.03% | Jun 2026 |
| Avidity Partners Management LP | 1.60M | 2.92% | 0.00% | Jun 2026 |
| Sio Capital Management, LLC | 1.59M | 2.91% | +1,275.57% | Jun 2026 |
| UBS Group AG | 1.49M | 2.72% | +231.85% | Jun 2026 |
| Geode Capital Management, LLC | 1.13M | 2.07% | +142.70% | Jun 2026 |
| Masters Capital Management LLC | 700K | 1.28% | +40.00% | Jun 2026 |
| State Street Corp | 511K | 0.93% | +183.51% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 406K | 0.74% | -12.64% | Jun 2026 |
| Bank of America Corp | 394K | 0.72% | +592.48% | Jun 2026 |
| Charles Schwab Investment Management Inc | 393K | 0.72% | +77.78% | Jun 2026 |
| Northern Trust Corp | 332K | 0.61% | +303.84% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 331K | 0.60% | +47.16% | Jun 2026 |
| Walleye Trading Advisors, LLC | 324K | 0.59% | 0.00% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 272K | 0.50% | 0.00% | Jun 2026 |
| The Goldman Sachs Group Inc | 232K | 0.42% | +58.26% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 165K | 0.30% | +33.11% | Jun 2026 |
| Trexquant Investment LP | 135K | 0.25% | 0.00% | Jun 2026 |
| Ghisallo Capital Management LLC | 125K | 0.23% | 0.00% | Jun 2026 |
Senseonics Holdings, Inc. Common Stock company profile
- Company name
- Senseonics Holdings, Inc. Common Stock
- Ticker
- SENS.US
- Exchange
- USA Stocks
- Listed since
- Mar 17, 2016
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 130
- Fiscal year end
- December
- Address
- 20451 Seneca Meadows Parkway, Germantown, MD, United States, 20876-7005
- Phone
- 301 515 7260
- Website
- senseonics.com
About Senseonics Holdings, Inc. Common Stock
Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. Its products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
Senseonics Holdings, Inc. Common Stock management
6- Dr. Timothy T. Goodnow Ph.D.President, CEO & Director · born 1962
- Mr. Frederick T. Sullivan CPACFO, Secretary & Treasurer · born 1982
- Dr. Mukul Jain Ph.D.Chief Operating Officer · born 1973
- Dr. Francine Ratner Kaufman M.D.Chief Medical Officer & Director · born 1951
- Mr. Brian B. HansenChief Commercial Officer & Director · born 1968
- Mr. Kenneth L. Horton J.D.General Counsel & Corporate Development Advisor · born 1967